Claims
- 1. A method for treating an individual suffering from an antibody-mediated pathology comprising administering to said individual an effective amount of an agent which interferes with C3d binding to CD21, whereby a symptom of the antibody-mediated pathology is ameliorated.
- 2. The method according to claim 1 wherein the antibody-mediated pathology is an autoimmune disease.
- 3. The method according to claim 2 wherein the autoimmune disease is systemic lupus erythematosus.
- 4. The method according to claim 1 wherein the antibody-mediated pathology is xenotransplantation rejection.
- 5. The method according to claim 1 wherein the antibody-mediated pathology is thyroiditis.
- 6. The method according to claim 1 wherein the agent is an antibody which specifically binds to a region of CD21 to which C3d binds.
- 7. The method according to claim 6 wherein said region comprises short consensus region 1 and short consensus region 2.
- 8. The method according to claim 6 wherein said region comprises short consensus region 1 or a portion thereof.
- 9. The method according to claim 6 wherein said region comprises short consensus region 2 or a portion thereof.
- 10. The method according to claim 1 wherein said agent is an antibody.
- 11. A method for delaying development of a symptom associated with an antibody-mediated pathology in an individual comprising administering to said individual an effective amount of an agent which interferes with C3d binding to CD21, wherein development of a symptom of the antibody-mediated pathology is delayed.
- 12. The method according to claim 11 wherein the antibody-mediated pathology is an autoimmune disease.
- 13. The method according to claim 12 wherein the autoimmune disease is systemic lupus erythematosus.
- 14. The method according to claim 11 wherein the antibody-mediated pathology is xenotransplantation rejection.
- 15. The method according to claim 11 wherein the antibody-mediated pathology is thyroiditis.
- 16. The method according to claim 11 wherein the agent is an antibody which specifically binds to a region of CD21 to which C3d binds.
- 17. The method according to claim 16 wherein said region comprises short consensus region 1 and short consensus region 2.
- 18. The method according to claim 16 wherein said region comprises short consensus region 1 or a portion thereof.
- 19. The method according to claim 16 wherein said region comprises short consensus region 2 or a portion thereof.
- 20. The method according to claim 11 wherein said agent is an antibody.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of U.S. provisional application serial No. 60/292,132, filed May 17, 2001, which is incorporated in its entirety by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60292132 |
May 2001 |
US |